Norepinephrine–dopamine disinhibitor (original) (raw)
Dysinhibitory noradrenaliny i dopaminy (ang. norepinephrine and dopamine disinhibitors, NDDI) – grupa leków, których mechanizm działania polega na odhamowaniu (dysinhibicji) uwalniania neuroprzekaźników noradrenaliny i dopaminy w korze przedczołowej poprzez antagonizm wobec receptorów serotoninergicznych 5HT2C. Działanie takie przypisuje się lekom przeciwdepresyjnym: agomelatynie (działającej poza tym na receptory melatoninergiczne) i fluoksetynie (której głównym mechanizmem działania jest hamowanie wychwytu zwrotnego serotoniny). Flibanseryna, lek zarejestrowany we wskazaniu zaburzeń pożądania u kobiet w okresie przedmenopauzalnym, odhamowuje uwalnianie noradrenaliny i dopaminy poprzez działanie na receptory 5HT1A.
| Property | Value |
|---|---|
| dbo:abstract | Norepinephrine and dopamine disinhibitors (NDDIs) are a class of drugs which act at specific sites to disinhibit downstream norepinephrine and dopamine release in the brain. Agomelatine, an antidepressant which disinhibits norepinephrine and dopamine release in the frontal cortex by antagonizing 5-HT2C receptors, was the first drug to be described as an NDDI. While many other drugs also antagonize 5-HT2C receptors to some degree or another, they tend to be very non-specific in their actions, and as a result, the term "NDDI" has generally, though not always (for instance, fluoxetine has been called an NDDI in addition to SSRI due to its (weak) blockade of 5-HT2C), been reserved for describing newer, more selective agents in which disinhibition of norepinephrine and dopamine release is their primary mechanism of action. Another drug that has been referred to as an NDDI in the medical literature is flibanserin, which is approved as a treatment for hypoactive sexual desire disorder in premenopausal women. Flibanserin disinhibits norepinephrine and dopamine release in the prefrontal cortex by activating 5-HT1A receptors in this area. Aside from agomelatine, fluoxetine, and flibanserin, as of present, no other drugs have been described as NDDIs in the medical literature, despite the fact that many other existing drugs possess effects consistent with those of the definition of an NDDI. In any case, more drugs labeled specifically as NDDIs may be seen in the future. (en) Dysinhibitory noradrenaliny i dopaminy (ang. norepinephrine and dopamine disinhibitors, NDDI) – grupa leków, których mechanizm działania polega na odhamowaniu (dysinhibicji) uwalniania neuroprzekaźników noradrenaliny i dopaminy w korze przedczołowej poprzez antagonizm wobec receptorów serotoninergicznych 5HT2C. Działanie takie przypisuje się lekom przeciwdepresyjnym: agomelatynie (działającej poza tym na receptory melatoninergiczne) i fluoksetynie (której głównym mechanizmem działania jest hamowanie wychwytu zwrotnego serotoniny). Flibanseryna, lek zarejestrowany we wskazaniu zaburzeń pożądania u kobiet w okresie przedmenopauzalnym, odhamowuje uwalnianie noradrenaliny i dopaminy poprzez działanie na receptory 5HT1A. (pl) |
| dbo:thumbnail | wiki-commons:Special:FilePath/Agomelatine.svg?width=300 |
| dbo:wikiPageID | 25760657 (xsd:integer) |
| dbo:wikiPageLength | 5333 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1097145637 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Frontal_cortex dbr:Noradrenergic_and_specific_serotonergic_antidepressant dbr:Brain dbr:Antidepressant dbr:Receptor_antagonist dbr:Medical_literature dbc:5-HT1A_agonists dbc:5-HT2C_antagonists dbr:Drug dbr:Agomelatine dbr:5-HT1A_receptor dbr:5-HT2C_receptor dbc:5-HT2A_antagonists dbc:Antidepressants dbr:Flibanserin dbr:Fluoxetine dbc:Female_sexual_dysfunction_drugs dbr:Norepinephrine dbr:Prefrontal_cortex dbr:Hypoactive_sexual_desire_disorder dbr:Binding_selectivity dbr:Dopamine dbr:Selective_serotonin_reuptake_inhibitor dbr:Serotonin_antagonist_and_reuptake_inhibitor dbr:Mechanism_of_action dbr:Serotonin_modulator_and_stimulator dbr:File:Agomelatine.svg |
| dbp:wikiPageUsesTemplate | dbt:Reflist dbt:Serotonin_receptor_modulators dbt:Short_description dbt:Antidepressants dbt:Sexual_dysfunction_pharmacotherapies |
| dcterms:subject | dbc:5-HT1A_agonists dbc:5-HT2C_antagonists dbc:5-HT2A_antagonists dbc:Antidepressants dbc:Female_sexual_dysfunction_drugs |
| gold:hypernym | dbr:Drugs |
| rdf:type | yago:Adversary109773245 yago:CausalAgent100007347 yago:LivingThing100004258 yago:Object100002684 yago:Organism100004475 yago:Person100007846 yago:PhysicalEntity100001930 yago:YagoLegalActor yago:YagoLegalActorGeo dbo:Drug yago:Whole100003553 yago:Wikicat5-HT2AAntagonists yago:Wikicat5-HT2CAntagonists |
| rdfs:comment | Dysinhibitory noradrenaliny i dopaminy (ang. norepinephrine and dopamine disinhibitors, NDDI) – grupa leków, których mechanizm działania polega na odhamowaniu (dysinhibicji) uwalniania neuroprzekaźników noradrenaliny i dopaminy w korze przedczołowej poprzez antagonizm wobec receptorów serotoninergicznych 5HT2C. Działanie takie przypisuje się lekom przeciwdepresyjnym: agomelatynie (działającej poza tym na receptory melatoninergiczne) i fluoksetynie (której głównym mechanizmem działania jest hamowanie wychwytu zwrotnego serotoniny). Flibanseryna, lek zarejestrowany we wskazaniu zaburzeń pożądania u kobiet w okresie przedmenopauzalnym, odhamowuje uwalnianie noradrenaliny i dopaminy poprzez działanie na receptory 5HT1A. (pl) Norepinephrine and dopamine disinhibitors (NDDIs) are a class of drugs which act at specific sites to disinhibit downstream norepinephrine and dopamine release in the brain. Agomelatine, an antidepressant which disinhibits norepinephrine and dopamine release in the frontal cortex by antagonizing 5-HT2C receptors, was the first drug to be described as an NDDI. While many other drugs also antagonize 5-HT2C receptors to some degree or another, they tend to be very non-specific in their actions, and as a result, the term "NDDI" has generally, though not always (for instance, fluoxetine has been called an NDDI in addition to SSRI due to its (weak) blockade of 5-HT2C), been reserved for describing newer, more selective agents in which disinhibition of norepinephrine and dopamine release is their (en) |
| rdfs:label | Norepinephrine–dopamine disinhibitor (en) Dysinhibitory noradrenaliny i dopaminy (pl) |
| owl:sameAs | freebase:Norepinephrine–dopamine disinhibitor wikidata:Norepinephrine–dopamine disinhibitor dbpedia-pl:Norepinephrine–dopamine disinhibitor https://global.dbpedia.org/id/4sjRu |
| prov:wasDerivedFrom | wikipedia-en:Norepinephrine–dopamine_disinhibitor?oldid=1097145637&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Agomelatine.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Norepinephrine–dopamine_disinhibitor |
| is dbo:wikiPageRedirects of | dbr:Norepinephrine-dopamine_disinhibitor dbr:Norepinephrine-dopamine_disinhibitors |
| is dbo:wikiPageWikiLink of | dbr:Agomelatine dbr:5-HT2C_receptor dbr:Flibanserin dbr:Norepinephrine-dopamine_disinhibitor dbr:Norepinephrine-dopamine_disinhibitors |
| is foaf:primaryTopic of | wikipedia-en:Norepinephrine–dopamine_disinhibitor |
